More fundamentally, though, they may at least partly explain phenomena such as why some atopic subjects who manufacture allergen-specific IgE do not develop allergic disease, and why in some patients with asthma, who may manufacture IgE inhibitory IgG endogenously, exogenously administered IgG anti-IgE therapy such as with omalizumab proffers little additional clinical benefit. Here, IGHE is linked to asthma.